Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04635852 | Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Cancer Patients | PHASE2 | COMPLETED | 10 | — | — | Mar 1, 2013 | Dec 1, 2014 | Nov 19, 2020 | 3 | Germany |
To determine the time to onset of meaningful breathlessness relief of fentanyl buccal tablet (FBT) in comparison to immediate-release morphine (IRM)
| Arm | Type | Description |
|---|---|---|
| Fentanyl | EXPERIMENTAL | Fentanyl buccal tablet Dosage: 100µg - 600 µg Fentanyl (to be determined by titration) Administration: buccal administration (tablet) |
| Immediate release morphine | ACTIVE_COMPARATOR | Immediate release morphine, solution Dosage: Start with a minimum of 5mg (to be determined by titration) |
| Name | Type | Description |
|---|---|---|
| Fentanyl | DRUG | - |
| Immediate release morphine | DRUG | - |
Inclusion criteria: 1. Histologically or cytologically proven cancer of any entity which is non-curable as judged by the referring physician or investigator 2. To be an inpatient during the study 3. Refractory breathlessness - this study applies only to 'refractory breathlessness ' and is defined: ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |